Correction: Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial

2024-9-6

Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial

2024-8-26

Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment

2024-8-26

Increased Odds of Cognitive Impairment in Adults with Depressive Symptoms and Antidepressant Use

2024-8-23

Twenty-Three Years of Declining Lithium Use: Analysis of a Pharmacoepidemiological Dataset from German-Speaking Countries

2024-8-22

Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point

2024-8-19

SARS-CoV-2-Infection in People Addicted to Illegal Drugs – Is There a Protective Effect of Opioid Maintenance Treatment?

2024-8-1

Recreational Cannabis Legalization: No Contribution to Rising Prescription Stimulants in the USA

2024-7-31

A Trajectory of Long-Term Antipsychotic Medication Dosage in Inpatients with Severe Behavioral and Psychological Symptoms of Dementia: A Retrospective Study

2024-6-25

Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study

2024-6-25

Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression

2024-6-19

Management of Refractory Functional Gastrointestinal Disorders: What Role Should Psychiatrists Have?

2024-6-19

Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

2024-5-6

Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments

2024-5-6

Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine

2024-5-6

Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group

2024-5-2

Medical Cannabis in Psychiatry

2024-5-1

Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder

2024-4-15

Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection

2024-3-26

Pharmacopsychiatry

2024-3-12

Medicinal Use of Different Cannabis Strains: Results from a Large Prospective Survey in Germany

2024-3-12

Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada – A Qualitative Study

2024-3-11

Cannabinoids for Behavioral Symptoms in Dementia: An Overview

2024-3-6

CYP2D6 genotypes and phenotypes, plasma levels and treatment failure with risperidone or aripiprazole: results from a one-year longitudinal study

2024-3-1

Clozapine Monitoring in Serum and Saliva

2024-3-1

Pharmacogenetics and TDM in patients with long-acting injectable antipsychotics: First clinical experience

2024-3-1

Development of the first consensus guidelines for therapeutic drug monitoring in Neuropsychopharmacology for children and adolescents

2024-3-1

International Guidelines of pharmacogenetic testing focusing on pharmacokinetically relevant genes and there relevance in neuropsychopharmacology

2024-3-1

Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis

2024-3-1

Psychotropic Medication and Breastfeeding – Yes – No – Maybe?

2024-3-1

Therapeutic drug monitoring in the opioid substitution treatment

2024-3-1

Implications of Online Self-Diagnosis in Psychiatry

2024-3-1

Systematic review on blood concentrations of ADHD medications in children and adolescents

2024-3-1

Therapeutic Drug Monitoring as part of the Opioid Withdrawal Therapy

2024-3-1

Equal contribution of pharmacogenetic phenotype and phenoconversion to functional CYP2D6 metabolizer status

2024-3-1

Update on the Management of Lithium in the Peripartum Period

2024-3-1

The influence of food on the pharmacokinetics of drugs

2024-3-1

Therapeutic Drug Monitoring of Antipsychotics: Innovations in the 2024 Consensus Guidelines

2024-3-1

Therapeutic Drug Monitoring (TDM) in addiction medicine from the laboratory perspective

2024-3-1

Degree of clinically quantified tolerance to the desired effects of and adverse drug reactions to the full mu opiod receptor agonist morphine, methadone and fentanyl and to the partial agonist buprenorphine during opioid maintenance and analgesic treatment

2024-3-1

Venlafaxine serum concentrations in children and adolescents – preliminary results of a multicenter Therapeutic Drug Monitoring trial

2024-3-1

Fluvoxamine serum concentrations in children and adolescents – preliminary results of a multicenter Therapeutic Drug Monitoring (TDM) trial

2024-3-1

Positron emission tomography for optimizing psychiatric drug treatment: present and future

2024-3-1

Drug-drug interaction between hydroxybupropion and venlafaxine – a pharmacokinetic study on CYP2D6

2024-3-1

Therapeutic drug monitoring of children and adolescents treated with escitalopram in daily clinical practice

2024-3-1

Establishing therapeutic drug monitoring to routinely assess pharmacokinetic changes for psychotropic medications prescribed during pregnancy and lactation

2024-3-1